摘要
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer worldwide and is a leading cause of morbidity and mortality in patients with cirrhosis (1). Although it is the second most common indication for liver transplantation in Europe (2), the optimal management of patients awaiting liver transplantation is still not established (3).
基金
supported by the Canadian Association for the Study of Liver and Canadian Liver Foundation.